Payment overview · 2025
General Payments
$40.72
2 reported records · 2 companies
Healthcare provider profile · identity verified
Daniel Williams, CRNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BRIDGEVILLE, PA · NPI 1104959907
Verified facts
What the public records show
CMS Open Payments records show Daniel Williams, CRNP received $40.72 in general payments during 2025 across 2 reported records.
ABBVIE INC. accounted for 58.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.75 | 58.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.97 | 41.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $40.72 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.75 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.75 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 173 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
60 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
173 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 599 | 198 |
| Levothyroxine Sodium | Levothyroxine Sodium | 370 | 96 |
| Lisinopril | Lisinopril | 367 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 358 | 114 |
| Pantoprazole Sodium | Pantoprazole Sodium | 280 | 92 |
| Gabapentin | Gabapentin | 237 | 54 |
| Metformin Hcl | Metformin Hcl | 182 | 55 |
| Simvastatin | Simvastatin | 182 | 56 |
| Alprazolam | Alprazolam | 176 | 58 |
| Eliquis | Apixaban | 173 | 38 |
| Furosemide | Furosemide | 172 | 58 |
| Omeprazole | Omeprazole | 156 | 45 |
| Losartan Potassium | Losartan Potassium | 155 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 148 | 43 |
| Sertraline Hcl | Sertraline Hcl | 147 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 140 | 34 |
| Lorazepam | Lorazepam | 139 | 35 |
| Trazodone Hcl | Trazodone Hcl | 128 | 34 |
| Atenolol | Atenolol | 114 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 110 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 110 | 32 |
| Warfarin Sodium | Warfarin Sodium | 107 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 104 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 101 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 101 | 33 |
| Allopurinol | Allopurinol | 85 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 43 |
| Carvedilol | Carvedilol | 81 | 25 |
| Irbesartan | Irbesartan | 80 | 19 |
| Jardiance | Empagliflozin | 79 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 68 | 26 |
| Famotidine | Famotidine | 68 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 65 | 25 |
| Tramadol Hcl | Tramadol Hcl | 65 | 28 |
| Mirtazapine | Mirtazapine | 60 | 15 |
| Synthroid | Levothyroxine Sodium | 60 | 17 |
| Potassium Chloride | Potassium Chloride | 59 | 22 |
| Pregabalin | Pregabalin | 59 | 12 |
| Prednisone | Prednisone | 58 | 49 |
| Buspirone Hcl | Buspirone Hcl | 56 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 18 |
| Ezetimibe | Ezetimibe | 50 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 43 |
| Meloxicam | Meloxicam | 43 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 42 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 40 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 38 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Valsartan | Valsartan | 36 | 13 |
| Celecoxib | Celecoxib | 35 | suppressed |
| Ibuprofen | Ibuprofen | 35 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 35 | suppressed |
| Finasteride | Finasteride | 34 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | 14 |
| Glipizide | Glipizide | 33 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Clonazepam | Clonazepam | 31 | 11 |
| Alendronate Sodium | Alendronate Sodium | 30 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Olanzapine | Olanzapine | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 15 |
| Ozempic | Semaglutide | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 25 |
| Jantoven | Warfarin Sodium | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 24 |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 21 |
| Colchicine | Colchicine | 21 | suppressed |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 18 |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 19 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Bethanechol Chloride | Bethanechol Chloride | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $40.72 · 2 records | ABBVIE INC. | ELIQUIS, NURTEC ODT, QULIPTA, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error